First, in patients with BRAF V600E WT SKCM, compared with the ICD-low group, the ICD-high group had significantly more immune-enhanced cell infiltration, immune-activated signaling pathway aggregation, tumor microenvironment effects, and a better clinical prognosis. Here, BRAF is linked to neoplasm.